Randomized Trial of Once-Daily Fluticasone Furoate in Children with Inadequately Controlled Asthma

    loading  Checking for direct PDF access through Ovid



To evaluate the dose-response, efficacy, and safety of fluticasone furoate (FF; 25 μg, 50 μg, and 100 μg), administered once daily in the evening during a 12-week treatment period to children with inadequately controlled asthma.

Study design

This was a Phase IIb, multicenter, stratified, randomized, double-blind, double-dummy, parallel-group, placebo- and active-controlled study in children aged 5-11 years with inadequately controlled asthma. The study comprised a 4-week run-in period, 12-week treatment period, and 1-week follow-up period. Children were randomized to receive either placebo once daily, fluticasone propionate (FP) 100 μg twice daily, FF 25 μg, FF 50 μg, or FF 100 μg each once daily in the evening. Primary endpoint was the mean change from baseline in daily morning peak expiratory flow (PEF) averaged over weeks 1-12. Adverse events (AEs) also were investigated.


In total, 593 children were included in the intent-to-treat population. The difference vs placebo in change from baseline daily morning PEF averaged over weeks 1-12 was statistically significant for the FF 25, FF 50, FF 100, and FP 100 groups (18.6 L/min, 19.5 L/min, 12.5 L/min, and 14.0 L/min, respectively; P < .001 for all). The incidence of AEs was greater in the FF groups (32%-36%) than in the placebo group (29%); the most frequent AE was cough.


FF and FP resulted in significant improvements in morning PEF compared with placebo, suggesting that they are effective treatments for children with inadequately controlled asthma. All treatments were well tolerated; no new safety concerns were identified.

Trial registration

ClinicalTrials.gov: NCT01563029.

Related Topics

    loading  Loading Related Articles